未登录

J

Jette A. van Lint

University of Amsterdam

H指数:6

被引数:128

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Fatigue patterns surrounding biologic disease-modifying antirheumatic drug injection in patients with an inflammatory rheumatic disease: an ecological momentary assessment study

RHEUMATOLOGY INTERNATIONAL

IF2.9

2025-01-110

OAAI

Quantification of longitudinal patient-reported burden of adverse drug reactions attributed to the use of TNF-α inhibitors in inflammatory rheumatic diseases: an observational prospective cohort study

EXPERT OPINION ON DRUG SAFETY

IF3.1

2024-08-300

PRE

The burden of adverse drug reactions reported by patients in the Dutch ADR monitor: a proof of concept

EXPERT OPINION ON DRUG SAFETY

IF3.1

2024-07-260

PRE

Hospital registration of adverse drug reactions in electronic health records: importance and contribution to pharmacovigilance

EXPERT OPINION ON DRUG SAFETY

IF3.1

2023-11-171

PRE

Development of a Framework Structuring Themes in the Course of Adverse Drug Reactions from a Patient's Perspective

IF3.8

2023-08-311

OAAI

Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor

生物制剂给药后的反复乏力: 来自荷兰生物监测仪的患者报告数据

IF6.9

2023-04-032

OAAI

Sex differences in adverse drug reactions from Adalimumab and etanercept in patients with inflammatory rheumatic diseases

EXPERT OPINION ON DRUG SAFETY

IF3.1

2023-03-011

PRE

First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept

EXPERT OPINION ON DRUG SAFETY

IF3.1

2023-01-273

OA

Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort study

炎性风湿性疾病患者报告的肿瘤坏死因子-α 抑制剂的疾病特异性不良反应: 一项基于登记的前瞻性多中心队列研究

EXPERT OPINION ON DRUG SAFETY

IF3.1

2022-08-280

OA

Neuropsychiatric adverse drug reactions associated with low dose methotrexate in rheumatoid arthritis patients

EXPERT OPINION ON DRUG SAFETY

IF3.1

2021-11-152

OA

Discrepancy between patient- and healthcare provider-reported adverse drug reactions in inflammatory bowel disease patients on biological therapy

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL

IF6.7

2021-06-028

OAAI

Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals

JOURNAL OF RHEUMATOLOGY

IF3.4

2021-05-150

OA

Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases

IF3.8

2020-05-2524

PREAI